Abstract
BackgroundPatients with mucopolysaccharidoses (MPS) are associated with poor bone growth and mineralization, however, information regarding the assessment of bone mineral density (BMD) in relation to age and treatment in this disorder is limited.MethodsDual energy x-ray absorptiometry (DXA) was performed in 30 patients with MPS (21 males and 9 females; 2 with MPS I, 12 with MPS II, 2 with MPS IIIB, 9 with MPS IVA, and 5 with MPS VI; median age, 10.8 years; age range, 5.0 years to 23.7 years; 26 patients were under 19 and 4 were above 19 years of age) to assess BMD of the lumbar spine (L1-L4), using the Hologic QDR 4500 system (Bedford, MA, USA).ResultsFor 26 patients under 19 years of age, standard deviation scores (z scores) for height, weight, body mass index (BMI), and BMD were −4.53 ± 2.66, -1.15 ± 1.55, 0.74 ± 1.23, and −3.03 ± 1.62, respectively, and they were all negatively correlated with age (p < 0.05). However, after correction for height-for-age z score (HAZ), HAZ adjusted BMD z score was −0.7 ± 1.24. Eight patients (31%) had osteopenia (HAZ adjusted BMD z score < −1 and ≥ −2), and 4 patients (15%) had osteoporosis (HAZ adjusted BMD z score < −2). Of 8 patients with MPS I, II or VI who underwent follow-up DXA after receiving enzyme replacement therapy for 1.0 to 7.4 years, all showed increase in absolute BMD values.ConclusionsThese findings and the follow-up data can be used to develop quality of care strategies for patients with MPS.
Highlights
The mucopolysaccharidoses (MPS; OMIM 252700) are a group of inherited lysosomal storage disorders caused by deficiencies in enzymes catalyzing the degradation of glycosaminoglycans (GAGs)
Fung et al [10] evaluated bone mineral density (BMD) by Dual energy x-ray absorptiometry (DXA) in 8 patients with MPS II or VI who were receiving enzyme replacement therapy (ERT) and found that BMD was within the normal range for most of the patients, after correction for short stature
We found that 46% (12/26) of the MPS study patients
Summary
The mucopolysaccharidoses (MPS; OMIM 252700) are a group of inherited lysosomal storage disorders caused by deficiencies in enzymes catalyzing the degradation of glycosaminoglycans (GAGs). Eleven known enzyme deficiencies give rise to 7 distinct types It is well-known that many children with chronic illnesses are at risk for low bone mass [4,5,6,7,8,9]. We evaluated BMD by DXA in patients with MPS, in relation to age and treatment with ERT. Patients with mucopolysaccharidoses (MPS) are associated with poor bone growth and mineralization, information regarding the assessment of bone mineral density (BMD) in relation to age and treatment in this disorder is limited
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.